Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Receivables - Other (2020 - 2023)

Historic Receivables - Other for GeneDx Holdings (WGS) over the last 4 years, with Q2 2023 value amounting to $2.9 million.

  • GeneDx Holdings' Receivables - Other fell 3353.2% to $2.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.9 million, marking a year-over-year decrease of 3353.2%. This contributed to the annual value of $1.5 million for FY2022, which is 5449.03% down from last year.
  • GeneDx Holdings' Receivables - Other amounted to $2.9 million in Q2 2023, which was down 3353.2% from $2.9 million recorded in Q1 2023.
  • GeneDx Holdings' Receivables - Other's 5-year high stood at $4.4 million during Q2 2022, with a 5-year trough of $54000.0 in Q4 2021.
  • Over the past 4 years, GeneDx Holdings' median Receivables - Other value was $1.5 million (recorded in 2022), while the average stood at $1.9 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first crashed by 8131.49% in 2021, then skyrocketed by 267777.78% in 2022.
  • Quarter analysis of 4 years shows GeneDx Holdings' Receivables - Other stood at $289000.0 in 2020, then tumbled by 81.31% to $54000.0 in 2021, then soared by 2677.78% to $1.5 million in 2022, then soared by 93.33% to $2.9 million in 2023.
  • Its Receivables - Other stands at $2.9 million for Q2 2023, versus $2.9 million for Q1 2023 and $1.5 million for Q4 2022.